Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer

Anticancer research

Volumn 36, Issue 1, 2016, Pages 307-312

  Kubota, Tetsuya ^a   Okano, Yoshio ^a   Sakai, Mizu ^a   Takaoka, Masato ^a   Tsukuda, Tsukie ^b   Anabuki, Kazuki ^a   Kawase, Shigeo ^a   Miyamoto, Shintaro ^a   Ohnishi, Hiroshi ^a   Hatakeyama, Nobuo ^b   Machida, Hisanori ^a   Urata, Tomoyuki ^a   Yamamoto, Akira ^a   Ogushi, Fumitaka ^a   Yokoyama, Akihito ^a  

^a National Hospital Organization Kochi National Hospital   (Japan)

^b Chikamori Hospital   (Japan)

Author keywords

bevacizumab; carboplatin; first line; Non small cell lung cancer; weekly paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES;

EID: 84973423108     PISSN: None     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (0)